Genomics & Biotech: Precision Medicine Is Rewriting Drug Development

The biggest drug companies in history were built on small molecules that blunted symptoms. The next generation is being built on reading, editing, and rewriting DNA. That shift is what the genomics-biotech theme captures across its 97 companies—and the competitive logic is fundamentally different from traditional pharma.

Instead of racing to patent a compound, the winners here own the delivery mechanism, the editing platform, or the data infrastructure that every downstream program depends on. That's why the theme rewards platform thinking over pipeline counting.

Base Editing Is the Next CRISPR Moment

Beam Therapeutics is the clearest expression of that logic. Beam's base-editing technology makes precise, single-letter changes to DNA without cutting the double helix—a meaningful improvement in safety profile over first-generation CRISPR approaches. The platform is not a single drug; it's a reusable engine. Every program Beam runs validates the underlying technology for the next one, compounding the IP moat with each clinical data readout.

Base editing is still early, but the genomics-biotech theme is full of companies in this position: the asset they're building is the capability, not just the indication.

The Tools and Services Layer Prints Revenue While Therapeutics Waits

Not every company in the theme is betting on clinical outcomes. Agilent Technologies sits at the analytical instruments end of the stack—mass spectrometry, liquid chromatography, genomic reagents. Every biotech running a discovery program buys Agilent's consumables. That makes Agilent structurally upstream of clinical risk: it gets paid whether the drug works or not.

IQVIA Holdings plays a similar role at the clinical operations layer. As genomic medicine drives increasingly complex trial designs—small patient populations, biomarker stratification, adaptive protocols—the demand for sophisticated CRO and real-world data infrastructure compounds. Fortrea Holdings operates in the same CRO corridor, giving the theme exposure to trial execution capacity that scales with the entire sector's pipeline.

This tools-and-services stratum is the theme's ballast. It doesn't generate the headline returns of a successful gene therapy, but it absorbs far less binary risk.

Radiopharmaceuticals and Niche Platforms Are the Sleeper Category

The loudest narrative in genomics runs through CRISPR and mRNA. The quieter one runs through targeted radiopharmaceuticals. Radiopharm Theranostics is developing radiopharmaceutical candidates that pair a targeting molecule with a radioactive payload—delivering radiation directly to tumor cells while sparing surrounding tissue. The FDA's approval of two radiopharmaceuticals in recent years has opened the category commercially, and smaller developers are now racing to extend the modality into new tumor types.

Celcuity takes a different angle: its platform identifies which cellular signaling pathways are actually driving a patient's cancer, then matches them to targeted therapies. That diagnostic-first approach is exactly what precision oncology promises—treatment decisions grounded in tumor biology rather than organ of origin.

The breadth of approaches across the genomics-biotech theme is itself the point. Base editing, radiopharmaceuticals, pathway diagnostics, and CRO infrastructure are not competing with each other. They are successive layers of the same infrastructure stack being built under precision medicine. Investors who understand which layer they're buying—and what the binary risks are at each level—have a significant edge over those treating the theme as a monolith. Explore the full ETF library for diversified exposure across the stack.